DLBCL: who is high risk and how should treatment be optimized?

2.

Sehn

L

,

Salles

G

.

Diffuse large B-cell lymphoma

.

N Engl J Med

.

2021

;

384

(

9

):

842

-

858

.

3.

Crump

M

,

Neelapu

SS

,

Farooq

U

, et al.

Outcomes in refractory diffuse large B-cell lymphoma: results from the International SCHOLAR-1 study

.

Blood

.

2017

;

130

(

16

):

1800

-

1808

.

4.

Gisselbrecht

C

,

Glass

B

,

Mounier

N

, et al.

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

.

J Clin Oncol

.

2010

;

28

(

27

):

4184

-

4190

.

5.

Westin

J

,

Oluwole

OO

,

Kersten

MJ

, et al.

Survival with axicabtagene ciloleucel in large B-cell lymphoma

.

N Engl J Med

.

2023

;

389

(

2

):

148

-

157

.

6.

Schuster

SJ

,

Tam

CS

,

Borchmann

P

, et al.

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

.

Lancet Oncol

.

2021

;

22

(

10

):

1403

-

1415

.

7.

Abramson

JS

,

Palomba

ML

,

Gordon

LI

, et al.

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

.

Lancet

.

2020

;

396

(

10254

):

839

-

852

.

8.

Neelapu

SS

,

Jacobson

CA

,

Ghobadi

A

, et al.

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

.

Blood

.

2023

;

141

(

19

):

2307

-

2315

.

9.

Kamdar

M

,

Solomon

SR

,

Arnason

J

, et al;

TRANSFORM Investigators

.

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

.

Lancet

.

2022

;

399

(

10343

):

2294

-

2308

. Erratum in Lancet. 2022;400(10347):160.

10.

International Non-Hodgkin's Lymphoma Prognostic Factors Project

.

A predictive model for aggressive non-Hodgkin's lymphoma

.

N Engl J Med

.

1993

;

329

(

14

):

987

-

994

.

11.

Sehn

LH

,

Berry

B

,

Chhanabhai

M

, et al.

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

.

Blood

.

2007

;

109

(

5

):

1857

-

1861

.

12.

Zhou

Z

,

Sehn

LH

,

Rademaker

AW

, et al.

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

.

Blood

.

2014

;

123

(

6

):

837

-

842

.

13.

Ruppert

AS

,

Dixon

JG

,

Salles

G

, et al.

International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI

.

Blood

.

2020

;

135

(

23

):

2041

-

2048

.

14.

Rosenwald

A

,

Wright

G

,

Chan

WC

, et al;

Lymphoma/Leukemia Molecular Profiling Project

.

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

.

N Engl J Med

.

2002

;

346

(

25

):

1937

-

1947

.

15.

Scott

DW

,

Mottok

A

,

Ennishi

D

, et al.

Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies

.

J Clin Oncol

.

2015

;

33

(

26

):

2848

-

2856

.

16.

Johnson

NA

,

Slack

GW

,

Savage

KJ

, et al.

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

.

J Clin Oncol

.

2012

;

30

(

28

):

3452

-

3459

.

17.

Green

TM

,

Young

KH

,

Visco

C

, et al.

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

.

J Clin Oncol

.

2012

;

30

(

28

):

3460

-

3467

.

18.

Hu

S

,

Xu-Monette

ZY

,

Tzankov

A

, et al.

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

.

Blood

.

2013

;

121

(

20

):

4021

-

4031

. quiz 4250.

19.

Johnson

NA

,

Savage

KJ

,

Ludkovski

O

, et al.

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

.

Blood

.

2009

;

114

(

11

):

2273

-

2279

.

20.

Oki

Y

,

Noorani

M

,

Lin

P

, et al.

Double hit lymphoma: the MD Anderson Cancer Center clinical experience

.

Br J Haematol

.

2014

;

166

(

6

):

891

-

901

.

21.

Petrich

AM

,

Gandhi

M

,

Jovanovic

B

, et al.

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

.

Blood

.

2014

;

124

(

15

):

2354

-

2361

.

22.

Dunleavy

K

,

Fanale

MA

,

Abramson

JS

, et al.

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study

.

Lancet Haematol

.

2018

;

5

(

12

):

e609

-

e617

.

23.

Ennishi

D

,

Jiang

A

,

Boyle

M

, et al.

Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma

.

J Clin Oncol

.

2019

;

37

(

3

):

190

-

201

.

24.

Schmitz

R

,

Wright

GW

,

Huang

DW

, et al.

Genetics and pathogenesis of diffuse large B-cell lymphoma

.

N Engl J Med

.

2018

;

378

(

15

):

1396

-

1407

.

25.

Chapuy

B

,

Stewart

C

,

Dunford

AJ

, et al.

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

.

Nat Med

.

2018

;

24

(

5

):

679

-

690

.

26.

Wright

GW

,

Huang

DW

,

Phelan

JD

, et al.

A Probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications

.

Cancer Cell

.

2020

;

37

(

4

):

551

-

568.e14

.

27.

Lacy

SE

,

Barrans

SL

,

Beer

P

, et al.

Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report

.

Blood

.

2020

;

135

(

20

):

1759

-

1771

.

28.

Schmitz

C

,

Hüttmann

A

,

Müller

SP

, et al.

Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: post-hoc analysis from the PETAL trial

.

Eur J Cancer

.

2020

;

124

:

25

-

36

.

29.

Thieblemont

C

,

Chartier

L

,

Dührsen

U

, et al.

A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma

.

Blood Adv

.

2022

;

6

(

23

):

5995

-

6004

.

30.

Mikhaeel

NG

,

Heymans

MW

,

Eertink

JJ

, et al.

Proposed new dynamic prognostic index for diffuse large B-cell lymphoma: International Metabolic Prognostic Index

.

J Clin Oncol

.

2022

;

40

(

21

):

2352

-

2360

.

31.

Eertink

JJ

,

Zwezerijnen

GJC

,

Heymans

MW

, et al.

Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma

.

Blood

.

2023

;

141

(

25

):

3055

-

3064

.

32.

Kurtz

DM

,

Scherer

F

,

Jin

MC

, et al.

Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma

.

J Clin Oncol

.

2018

;

36

(

28

):

2845

-

2853

.

33.

Maurer

MJ

,

Ghesquières

H

,

Link

BK

, et al.

Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials

.

J Clin Oncol

.

2018

;

36

(

16

):

1603

-

1610

.

34.

Drake

MT

,

Maurer

MJ

,

Link

BK

, et al.

Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma

.

J Clin Oncol

.

2010

;

28

(

27

):

4191

-

4198

.

35.

Gauchy

A-C

,

Kanagaratnam

L

,

Quinquenel

A

, et al.

Hypercalcemia at diagnosis of diffuse large B-cell lymphoma is not uncommon and is associated with high-risk features and a short diagnosis-to-treatment interval

.

Hematol Oncol

.

2020

;

38

(

3

):

326

-

333

.

36.

Porrata

LF

,

Ristow

K

,

Habermann

TM

, et al.

Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma

.

Leuk Lymphoma

.

2012

;

53

(

11

):

2159

-

2165

.

37.

Vitolo

U

,

Nowakowski

GS

,

Burke

JM

, et al.

FRONT-MIND: a phase III, randomized, double-blind study of tafasitamab+lenalidomide+R-CHOP vs R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma

.

Hemasphere

.

2022

;

6

(

suppl

):

1984

-

1985

.

38.

Alizadeh

AA

,

Eisen

MB

,

Davis

RE

, et al.

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

.

Nature

.

2000

;

403

(

6769

):

503

-

511

.

39.

Sehn

LH

,

Martelli

M

,

Trněný

M

, et al.

A randomized, open-label, phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma: final analysis of GOYA

.

J Hematol Oncol

.

2020

;

13

(

1

):

71

.

40.

Younes

A

,

Sehn

LH

,

Johnson

P

, et al.

Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma

.

J Clin Oncol

.

2019

;

37

(

15

):

1285

-

1295

.

41.

Nowakowski

GS

,

Chiappella

A

,

Gascoyne

RD

, et al.

ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma

.

J Clin Oncol

.

2021

;

39

(

12

):

1317

-

1328

.

42.

Hans

CP

,

Weisenburger

DD

,

Greiner

TC

, et al.

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

.

Blood

.

2004

;

103

(

1

):

275

-

282

.

43.

Visco

C

,

Li

Y

,

Xu-Monette

ZY

, et al.

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium

.

Leukemia

.

2012

;

26

(

9

):

2103

-

2113

.

44.

Choi

WWL

,

Weisenburger

DD

,

Greiner

TC

, et al.

A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy

.

Clin Cancer Res

.

2009

;

15

(

17

):

5494

-

5502

.

45.

Gutiérrez-García

G

,

Cardesa-Salzmann

T

,

Climent

F

, et al.

Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

.

Blood

.

2011

;

117

(

18

):

4836

-

4843

.

46.

Read

JA

,

Koff

JL

,

Nastoupil

LJ

,

Williams

JN

,

Cohen

JB

,

Flowers

CR

.

Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms

.

Clin Lymphoma Myeloma Leuk

.

2014

;

14

(

6

):

460

-

467.e2

.

47.

Campo

E

,

Jaffe

ES

,

Cook

JR

, et al.

The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee

.

Blood

.

2022

;

140

(

11

):

1229

-

1253

. Erratum in Blood. 2023;141(4):437.

48.

Cunningham

D

,

Hawkes

E

,

Jack

A

, et al.

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

.

Lancet

.

2013

;

381

(

9880

):

1817

-

1826

.

49.

Hilton

LK

,

Tang

J

,

Ben-Neriah

S

, et al.

The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH

.

Blood

.

2019

;

134

(

18

):

1528

-

1532

.

50.

de Leval

L

,

Alizadeh

AA

,

Bergsagel

PL

, et al.

Genomic profiling for clinical decision making in lymphoid neoplasms

.

Blood

.

2022

;

140

(

21

):

2193

-

2227

.

51.

Vercellino

L

,

Cottereau

A-S

,

Casasnovas

O

, et al.

High total metabolic tumor volume at baseline predicts survival independent of response to therapy

.

Blood

.

2020

;

135

(

16

):

1396

-

1405

.

52.

Toledano

MN

,

Desbordes

P

,

Banjar

A

, et al.

Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma

.

Eur J Nucl Med Mol Imaging

.

2018

;

45

(

5

):

680

-

688

.

53.

Cottereau

A-S

,

Meignan

M

,

Nioche

C

, et al.

Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT

.

Ann Oncol

.

2021

;

32

(

3

):

404

-

411

.

54.

Eertink

JJ

,

van de Brug

T

,

Wiegers

SE

, et al.

(18)F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma

.

Eur J Nucl Med Mol Imaging

.

2022

;

49

(

3

):

932

-

942

.

55.

Burggraaff

CN

,

de Jong

A

,

Hoekstra

OS

, et al.

Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis

.

Eur J Nucl Med Mol Imaging

.

2019

;

46

(

1

):

65

-

79

.

56.

Eertink

JJ

,

Burggraaff

CN

,

Heymans

MW

, et al.

Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients

.

Blood Adv

.

2021

;

5

(

9

):

2375

-

2384

.

57.

Scherer

F

,

Kurtz

DM

,

Newman

AM

, et al.

Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA

.

Sci Trans Med

.

2016

;

8

(

364

):

364ra155

.

58.

Herrera

AF

,

McCord

R

,

Kimes

P

, et al.

Risk profiling of patients with previously untreated diffuse large B-cell lymphoma (DLBCL) by measuring circulating tumor DNA (ctDNA): results from the POLARIX study [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

1297

-

1300

.

59.

Meriranta

L

,

Alkodsi

A

,

Pasanen

A

, et al.

Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma

.

Blood

.

2022

;

139

(

12

):

1863

-

1877

.

60.

Kurtz

DM

,

Esfahani

MS

,

Scherer

F

, et al.

Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction

.

Cell

.

2019

;

178

(

3

):

699

-

713.e19

.

61.

Récher

C

,

Coiffier

B

,

Haioun

C

, et al.

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial

.

Lancet

.

2011

;

378

(

9806

):

1858

-

1867

.

62.

Schmitz

N

,

Nickelsen

M

,

Ziepert

M

, et al.

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)

.

Lancet Oncol

.

2012

;

13

(

12

):

1250

-

1259

.

63.

Bartlett

NL

,

Wilson

WH

,

Jung

S-H

, et al.

Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III Intergroup Trial Alliance/CALGB 50303

.

J Clin Oncol

.

2019

;

37

(

21

):

1790

-

1799

.

64.

Chiappella

A

,

Martelli

M

,

Angelucci

E

, et al.

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

.

Lancet Oncol

.

2017

;

18

(

8

):

1076

-

1088

.

65.

Stiff

PJ

,

Unger

JM

,

Cook

JR

, et al.

Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma

.

N Engl J Med

.

2013

;

369

(

18

):

1681

-

1690

.

66.

Tilly

H

,

Morschhauser

F

,

Sehn

LH

, et al.

Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma

.

N Engl J Med

.

2022

;

386

(

4

):

351

-

363

.

67.

Davies

A

,

Cummin

TE

,

Barrans

S

, et al.

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial

.

Lancet Oncol

.

2019

;

20

(

5

):

649

-

662

.

68.

Davies

AJ

,

Barrans

S

,

Stanton

L

, et al.

Differential efficacy from the addition of bortezomib to R-CHOP in diffuse large B-cell lymphoma according to the molecular subgroup in the REMoDL-B Study with a 5-year follow-up

.

J Clin Oncol

.

2023

;

41

(

15

):

2718

-

2723

.

69.

Wilson

WH

,

Wright

GW

,

Huang

DW

, et al.

Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL

.

Cancer Cell

.

2021

;

39

(

12

):

1643

-

1653.e3

.

70.

Acalabrutinib in combination with R-CHOP for previously untreated diffuse large B-cell lymphoma (DLBCL) (REMoDL-A)

.

ClinicalTrials.gov identifier: NCT04546620

. Updated 28 October 2022. Accessed 17 November 2023. https://classic.clinicaltrials.gov/ct2/show/NCT04546620.

71.

A combination of acalabrutinib with R-CHOP in subjects with previously untreated non-GCB DLBCL (ACE-Ly-312) (ESCALADE)

.

ClinicalTrials.gov identifier: NCT04529772

. Updated 14 November 2023. Accessed 17 November 2023. https://classic.clinicaltrials.gov/ct2/show/NCT04529772.

72.

Nowakowski

GS

,

Hong

F

,

Scott

DW

, et al.

Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a randomized phase II US Intergroup Study ECOG-ACRIN E1412

.

J Clin Oncol

.

2021

;

39

(

12

):

1329

-

1338

.

73.

Tafasitamab+lenalidomide+R-CHOP versus R-CHOP in newly diagnosed high-intermediate and high risk DLBCL patients (frontMIND)

.

ClinicalTrials.gov identifier: NCT04824092

. Updated 6 April 2023. Accessed 17 November 2023. https://www.clinicaltrials.gov/study/NCT04824092.

74.

Dührsen

U

,

Müller

S

,

Hertenstein

B

, et al.

Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial

.

J Clin Oncol

.

2018

;

36

(

20

):

2024

-

2034

.

75.

Sehn

LH

,

Hardy

ELG

,

Gill

KK

, et al.

Phase 2 trial of interim PET scan-tailored therapy in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC) [abstract]

.

Blood

.

2014

;

124

(

21

):

392

.

76.

Swinnen

LJ

,

Li

H

,

Quon

A

, et al.

Response-adapted therapy for aggressive non-Hodgkin’s lymphomas based on early [18F]FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404)

.

Br J Haematol

.

2015

;

170

(

1

):

56

-

65

.

77.

Moskowitz

CH

,

Schöder

H

,

Teruya-Feldstein

J

, et al.

Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-Cell lymphoma

.

J Clin Oncol

.

2010

;

28

(

11

):

1896

-

1903

.

78.

Assessing a ctDNA and PET-oriented therapy in patients with DLBCL

.

A multicenter, open-label, phase 2 trial. ClinicalTrials.gov identifier: NCT04604067

. Updated 18 April 2023. Accessed 17 November 2023. https://classic.clinicaltrials.gov/ct2/show/NCT04604067.

79.

Neelapu

SS

,

Dickinson

M

,

Munoz

J

, et al.

Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial

.

Nat Med

.

2022

;

28

(

4

):

735

-

742

.

80.

A study to compare axicabtagene ciloleucel with standard of care therapy as first-line treatment in participants with high-risk large B-cell lymohoma (ZUMA 23)

.

ClinicalTrials.gov identifier: NCT05605899

. Updated 23 October 2023. Accessed 17 November 2023. https://classic.clinicaltrials.gov/ct2/show/NCT05605899.

81.

Dickinson

MJ

,

Carlo-Stella

C

,

Morschhauser

F

, et al.

Glofitamab for relapsed or refractory diffuse large B-cell lymphoma

.

N Engl J Med

.

2022

;

387

(

24

):

2220

-

2231

.

82.

Thieblemont

C

,

Phillips

T

,

Ghesquieres

H

, et al.

Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial

.

J Clin Oncol

.

2023

;

41

(

12

):

2238

-

2247

.

83.

Topp

MS

,

Tani

M

,

Dickinson

M

, et al.

Glofitamab plus R-CHOP induces high response rates and a favorable safety profile in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): results from a phase Ib study [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

1775

-

1777

.

84.

A phase II study of glofitamab + polatuzumab-R-CHP for patients with high-risk diffuse large B-cell lymphoma

.

ClinicalTrials.gov identifier: NCT05800366

. Updated 13 September 2023. Accessed 17 November 2023. https://classic.clinicaltrials.gov/ct2/show/NCT05800366.

85.

Falchi

L

,

Clausen

M

,

Offner

O

, et al.

Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: updated EPCORE NHL-2 data

.

J Clin Oncol

.

2023

;

41

(

16

):

7519

.

86.

A study to evaluate change in disease activity in subcutaneous (sc) epcoritamab combined with intravenous and oral rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisone (R-CHOP) or R-CHOP in adult participants with newly diagnosed diffuse large B-cell lymphoma (DLBCL) (EPCORE DLBCL-2). ClinicalTrials.gov identifier: NCT05578976

. Updated 14 November 2023. Accessed 17 November 2023. https://www.clinicaltrials.gov/study/NCT05578976.

87.

Palmer

AC

,

Kurtz

DM

,

Alizadeh

AA

.

Cell-of-origin subtypes and therapeutic benefit from polatuzumab vedotin

.

N Engl J Med

.

2023

;

389

(

8

):

764

-

766

.